BetterLife Obtains Excellent Animal Cardiopulmonary Safety

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: Peter /OTCBC: Brilliant /fra: NPAU), a biotechnology startup focused on developing BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced that it has completed an animal cardiopulmonary safety study of BETR-001. The study showed that oral BETR-001 at doses greater than 100 times the expected starting dose in upcoming human trials showed no significant cardiopulmonary drug safety issues in animals.

Cardiopulmonary safety studies (also known as telemetry) look at the effect of a drug in animals using surgically implanted transmitters to evaluate blood pressure, electrocardiogram (ECG), lung breathing, body temperature, and general activity level. The BETR-001 Heart and Lung Study found no relevant effects of BETR-001 on ECG intervals, respiratory parameters, core body temperature, or activity levels.

Dr. Ahmed Doroudian, CEO of BetterLife, commented: “We are very excited about these results. BETR-001 is a unique non-hallucinogenic derivative of LSD with potent activity in animal models of depression and anxiety without the burden of hallucinations. Our previous neuroreceptor pharmacology studies in vitro (Cell Report 2023) showed that BETR-001 is not a 5-HT2B receptor agonist. This is in marked contrast to LSD, psilocybin, and many other serotonergic drugs known to be 5-HT2B receptor agonists. 5-HT2B receptor agonism is a known cause of cardiotoxicity (Pharmacol. there. 2011). The clean safety profile of BETR-001 in our completed animal cardiopulmonary study also supports the claim that BETR-001 shows a significantly better cardiac safety profile compared to LSD, psilocybin and other serotonergic narcotics with 5-HT2B activity.

“We are currently completing the remaining studies to enable the BETR-001 IND and the project to submit the BETR-001 IND by the end of 2024,” Dr. Dorodian added.

The Company also announces that it has issued 1,035,342 common shares and 1,035,342 stock purchase warrants pursuant to the conversion of principal and accrued interest on convertible notes totaling $103,534.20. Warrants to purchase shares of common stock may be exercised, on a one-for-one basis, with an exercise price of $0.10 per warrant and expire on December 31, 2025.

About Better Life Pharma

BetterLife Pharma Inc. is a biotechnology startup primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, for the treatment of neuropsychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic, non-controlled LSD derivative in development that is unique in that it is unregulated and therefore self-administered. BetterLife’s combination patent for BETR-001 clears regulatory hurdles, and the pending patent, with respect to composition and method of use, covers the treatment of major depressive disorder, anxiety disorder, neuropathic pain and other neuropsychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient in magnolia bark. BetterLife’s patent-pending method of use covers the treatment of anxiety-related disorders including benzodiazepine dependence.

BetterLife also has a drug candidate for treating viral infections and is in the process of investigating strategic alternatives for further development.

For more information, please visit Pharma Better Life.


David Mills, Director of Investor Relations
e-mail: David.Melles@blifepharma.com
Phone: 1-778-887-1928

Cautionary note regarding forward-looking statements

No stock exchange has reviewed or accepts responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements relating to product development, licensing, marketing, regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may,” “should,” “expect,” “anticipate” and similar expressions. All statements, other than statements of historical fact, contained in this release are forward-looking statements that involve risks and uncertainties. Such statements cannot be guaranteed to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in filings the Company makes with securities regulations. The reader is cautioned that the assumptions used in preparing any forward-looking information may prove to be incorrect. Events or conditions may cause actual results to differ materially from those anticipated, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control. The reader is cautioned not to place undue reliance on any forward-looking information. Although such information is considered reasonable by management at the time of preparation, it may prove incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will publicly update or revise any included forward-looking statements as expressly required by applicable law.

BetterLife Obtains Excellent Animal Cardiopulmonary Safety

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button

Adblock Detected